


Supplementary figure 1: Relative expression levels of A) EphA2, B) CAV-1, C) ANXA1, D) CAV-2, E) IGFBP2 and F) PTRF mRNA measured by qRT-PCR. Relative expression is measured compared to the control mix (a combination of equal amounts of mRNA from each cell line tested). Black bars represent dasatinib resistant cell lines; grey bars represent dasatinib sensitive cell lines. A result less than 1 indicates lower expression than the control whilst a result of greater than 1 indicates elevated expression relative to the control. Error bars represent standard deviations for triplicate qRT-PCR results.



Supplementary figure 2: Relative expression levels of A) ANXA1, B) CAV-1, C) EphA2, D) CAV-2, E) IGFBP2 and F) PTRF protein levels measured by western blotting. Relative expression was measured by densitometry measurement of band intensities compared to the  $\alpha$ -tubulin endogenous control. Black bars represent dasatinib resistant cell lines; grey samples represent dasatinib sensitive cell lines. Error bars represent standard deviations for triplicate independent experiments.

Supplementary Table 1: Correlation between each of the individual markers and combinations of the markers, and sensitivity to dasatinib. Each cell line was categorized as a high or low expressor for the individual markers using the median level of expression as a cut-off.

	<b>Chi-Squared test, p value</b>
ANXA1	0.0285
CAV-1	0.0285
EphA2	0.0047
ANXA1 + CAV-1	0.0183
ANXA1 + EphA2	0.0907
CAV-1 + EphA2	0.0907
ANXA1 + CAV-1 + EphA2	0.0183

Supplementary Table 2: Pearson Rank correlation between mRNA and protein levels in ANXA1, CAV-1, EphA2, CAV-2, IGFBP2 and PTRF.

<b>Biomarker</b>	<b>mRNA vs protein levels</b>	
ANXA1	p = 0.115	r = 0.619
CAV-1	p = 0.002	r = 0.881
EphA2	p = 0.058	r = 0.714
CAV-2	p = 0.619	r = 0.214
IGFBP2	p = 0.665	r = 0.190
PTRF	p = 0.229	r = 0.429

Supplementary table 3: Clinicopathological characteristics of patient samples used for immunohistochemical analysis of ANXA1, CAV-1 and EphA2 expression.

<b>Characteristic</b>	<b>Primary melanoma n = 82</b>	<b>Metastatic melanoma n = 42</b>
<b>Age (years)</b>		
≤ 60	26 (32 %)	16 (38 %)
> 60	56 (68 %)	26 (62 %)
<b>Gender</b>		
Male	25 (30 %)	21 (50 %)
Female	57 (70 %)	21 (50 %)
<b>Breslow thickness (mm)</b>		
Unknown	13 (21 %)	
< 1	27 (39 %)	
1 – 1.9	10 (14 %)	
2 – 3.9	12 (17 %)	
> 4	20 (29 %)	
Grouping 0 - 2	37 (54 %)	
Grouping > 2	32 (46 %)	
<b>Clarke's Level</b>		
Unknown	19 (23 %)	
I	0 (0 %)	
II	8 (13 %)	
III	28 (44 %)	
IV	20 (32 %)	
V	7 (11 %)	
<b>Lymph node status</b>		
Unknown	55 (67 %)	
Positive	6 (22 %)	
Negative	21 (78 %)	

Supplementary table 4: Correlation between clinico-pathological factors and number of SRC positive tumours; percentage of tumour cells positive for SRC expression (0 = 0%; 1 = <25 %; 2 = >25 % - <50 %; 3 = ≥50 %); and intensity of SRC staining in tumour cells in primary melanoma specimens (0 = negative; 1 = weak; 2 = moderate; 3 = strong). ‘\*’ indicates a P value of < 0.05 as determined by Chi-Squared or Kruskal-Wallis test.

SRC Kinase	Characteristic	SRC positive	% tumour cells positive for SRC			Intensity of staining in tumour cells			
			0	≤ 50	> 50	0	1	2	3
Age	< 60 years	25	2/27	11/27	14/27	2/27	6/27	12/27	7/27
	≥ 60 years	41	14/55	19/55	22/55	14/55	9/55	14/55	18/55
Gender	Male	22	3/25	8/25	14/25	3/25	4/25	8/25	10/25
	Female	44	13/57	22/57	22/57	13/57	11/57	18/57	15/57
SLN Status	Positive	4	2/6	3/6	1/6	2/6	3/6	0/6	1/6
	Negative	18	3/21	7/21	11/21	3/21	3/21	6/21	9/21
Clark’s level	II	8	0/8	4/8	4/8	0/8	3/8	2/8	3/8
	III	23	5/28	8/28	15/28	5/28	1/28	14/28	8/28
	IV	17	3/20	9/20	8/20	3/20	5/20	4/20	8/20
	V	6	1/7	2/7	4/7	1/7	2/7	1/7	3/7
Grouped Clarke’s level	< 4	31	5/36	12/36	19/36	5/36	4/36	16/36	11/36*
	4, 5	23	4/27	11/27	12/27	4/27	7/27	5/27	11/27
Breslow thickness		57	12/69	26/69	31/69	12/69	14/69	21/69	22/69
	< 1	22	5/27	10/27	12/27	5/27	7/27	9/27	6/27
Breslow thickness (mm)	1.0 – 1.9	7	3/10	3/10	4/10	3/10	0/10	3/10	4/10
	2.0 – 3.9	10	2/12	4/12	6/12	2/12	1/12	6/12	3/12
	> 4	18	2/20	9/20	9/20	2/20	6/20	3/20	9/20
Breslow grouped	≤ 2	30	8/38	14/38	16/38	8/38	7/38	13/38	10/38
	> 2	27	4/31	12/31	15/31	4/31	7/31	8/31	12/31

Supplementary table 5: Correlation between clinico-pathological factors and number of ANXA1 positive tumours; percentage of tumour cells positive for ANXA1 expression (0 = 0%; 1 = <25 %; 2 = >25 % - <50 %; 3 = ≥50 %); and intensity of ANXA1 staining in tumours in primary melanoma specimens (0 = negative; 1 = weak; 2 = moderate; 3 = strong). ‘\*’ indicates a P value of < 0.05 as determined by Chi-Squared or Kruskal-Wallis test.

	ANXA1	ANXA1 Positive	% of tumor cells positive for ANXA1				Intensity of ANXA1 staining			
			0	1	2	3	0	1	2	3
<b>Age</b>	< 60 years	22	3/25	7/25	5/25	10/25	3/25	3/25	9/25	10/25
	≥ 60 years	45	11/56	18/56	9/56	18/56	11/56	2/56	16/56	27/56
<b>Gender</b>	Male	22	2/24	7/24	4/24	11/24	2/24	3/24	7/24	12/24
	Female	45	12/57	18/57	10/57	17/57	12/57	2/57	18/57	25/57
<b>SLN status</b>	Positive	5	1/6	2/6	0/6	3/6	1/6	0/6	2/6	3/6
	Negative	17	4/21	9/21	3/21	5/21	4/21	2/21	8/21	7/21
<b>Clarke’s level</b>	2	6	1/7	1/7	2/7	3/7	1/7	2/7	2/7	2/7
	3	26	3/29	9/29	7/29	10/29	3/29	1/29	10/29	15/29
	4	15	5/20	3/20	5/20	7/20	5/20	0/20	5/20	10/20
	5	5	1/6	2/6	0/6	3/6	1/6	0/6	1/6	4/6
	≤ 4	32	4/36	10/36	9/36	13/36	4/36	3/36	12/36	17/36
<b>Grouped Clarke’s level</b>	4,5	20	6/26	5/26	5/26	10/26	6/26	0/26	6/26	14/26
<b>Breslow thickness</b>		56	11/67	18/67	14/67	24/67	11/67	3/67	21/67	32/67 *
<b>Breslow thickness (mm)</b>	< 1	24	3/27	9/27	9/27	6/27	3/27	2/27	12/27	10/27
	1.0 – 1.9	7	3/10	3/10	1/10	4/10	3/10	0/10	4/10	3/10
	2.0 – 3.9	10	1/11	2/11	2/11	5/11	1/11	1/11	1/11	8/11
	> 4	15	4/19	4/19	2/19	9/19	4/19	0/19	4/19	11/19
<b>Breslow grouped</b>	≤ 2	32	6/38	12/38	10/38	10/38	6/38	2/38	16/38	14/38
	> 2	24	5/29	6/29	4/29	14/29	5/29	1/29	5/29	18/29

Supplementary table 6: Correlation between clinico-pathological factors and number of CAV-1 positive tumours; percentage of tumour cells positive for CAV-1 expression (0 = 0%; 1 = <25 %; 2 = >25 % - <50 %; 3 = ≥50 %); and intensity of CAV-1 staining in tumour cells in primary melanoma specimens (0 = negative; 1 = weak; 2 = moderate; 3 = strong). ‘\*’ indicates a P value of < 0.05 as determined by Chi-Squared or Kruskal-Wallis test.

	Caveolin-1	CAV-1 Positive	% of tumor cells positive for CAV-1				Intensity of staining in tumor cells			
			0	1	2	3	0	1	2	3
<b>Age</b>	< 60 years	19 *	8/27	12/27	4/27	3/27*	8/27	7/27	7/27	5/27*
	≥ 60 years	20	35/55	8/55	10/55	2/55	35/55	3/55	11/55	6/55
<b>Gender</b>	<b>Female</b>	24	34/58	10/58	9/58	5/55*	34/58	6/58	10/58	8/58
	<b>Male</b>	15	9/24	10/24	5/24	0/24	9/24	4/24	8/24	3/24
<b>SLN status</b>	<b>Positive</b>	4	2/6	1/6	2/6	1/6	2/6	0/6	2/6	2/6
	<b>Negative</b>	11	10/21	5/21	4/21	2/21	10/21	3/21	3/21	5/21
<b>Clarkes level</b>	<b>2</b>	7	1/8	5/8	1/8	1/8	1/8	3/8	3/8	1/8
	<b>3</b>	13	16/29	6/29	4/29	3/29	16/29	4/29	4/29	5/29
	<b>4</b>	10	9/19	4/19	5/19	1/19	9/19	2/19	5/19	3/19
	<b>5</b>	5	2/7	1/7	4/7	0/7	2/7	0/7	3/7	2/7
	<b>≤ 4</b>	20	17/37	11/37	5/37	4/37	17/37	7/37	7/37	6/37
<b>Grouped Clarke’s level</b>	<b>4,5</b>	15	11/26	5/26	9/26	1/26	11/26	2/26	8/26	5/26
<b>Breslow thickness</b>		35	34/69	16/69	14/69	5/69	34/69	9/69	15/69	11/69
<b>Breslow thicknes (mm)</b>	< 1	17	11/28	9/28	5/28	3/28	10/28	5/28	8/28	5/28
	<b>1.0 – 1.9</b>	3	6/9	1/9	2/9	0/9	6/9	1/9	1/9	1/9
	<b>2.0 – 3.9</b>	3	9/12	2/12	0/12	1/12	9/12	1/12	1/12	1/12
	> 4	12	8/20	4/20	7/20	1/20	8/20	2/20	6/20	4/20
<b>Breslow grouped</b>	≤ 2	21	17/38	11/38	7/38	3/38	17/38	7/38	8/38	6/38
	> 2	14	17/31	5/31	7/31	2/31	17/31	2/31	7/31	5/31



Supplementary table 7: Correlation between clinico-pathological factors and number of EphA2 positive tumours; percentage of tumour cells positive for EphA2 expression (0 = 0%; 1 = <25 %; 2 = >25 % - <50 %; 3 = ≥50 %); and intensity of EphA2 staining in tumour cells in primary melanoma specimens (0 = negative; 1 = weak; 2 = moderate; 3 = strong). ‘\*’ indicates a P value of < 0.05 as determined by Chi-Squared or Kruskal-Wallis test.

EphA2	EphA2 Positive	% of tumor cells positive for EphA2				Intensity of staining in tumor cells				
		0	1	2	3	0	1	2	3	
<b>Age</b>	<b>&lt; 60 years</b>	24	3/27	5/27	4/27	15/27	3/27	2/27	10/27	12/27
	<b>≥ 60 years</b>	44	11/55	6/55	16/55	22/55	11/55	12/55	20/55	12/55
<b>Gender</b>	<b>Female</b>	48	9/57	7/57	17/57	24/57	9/57	10/57	25/57	13/57
	<b>Male</b>	20	5/25	4/25	3/25	13/25	5/25	4/25	5/25	11/25
<b>SLN status</b>	<b>Positive</b>	5	1/6	1/6	0/6	4/6	1/6	1/6	1/6	3/6
	<b>Negative</b>	17	4/21	4/21	4/21	9/21	4/21	3/21	10/21	4/21
<b>Clarkes level</b>	<b>2</b>	8	0/8	1/8	2/8	5/8	0/8	1/8	4/8	3/8
	<b>3</b>	23	4/27	2/27	9/27	12/27	4/27	4/27	9/27	10/27
	<b>4</b>	17	3/20	1/20	4/20	12/20	3/20	5/20	6/20	6/20
	<b>5</b>	7	0/7	1/7	3/7	3/7	0/7	3/7	3/7	1/7
<b>Grouped Clarke’s level</b>	<b>Level ≤ 4</b>	31	4/35	3/35	11/35	17/35	4/35	5/35	13/35	13/35
	<b>Level 4,5</b>	24	3/27	2/27	7/27	15/27	3/27	8/27	9/27	7/27
<b>Breslow thickness</b>		58	10/68	6/68	19/68	33/68	10/68	13/68	23/68	22/68
<b>Breslow thickness (mm)</b>	<b>&lt; 1</b>	21	5/26	1/26	9/26	11/26	5/26	2/26	11/26	8/26
	<b>1.0 – 1.9</b>	8	2/10	0/10	3/10	5/10	2/10	2/10	5/10	1/10
	<b>2.0 – 3.9</b>	12	0/12	4/12	2/12	6/12	0/12	3/12	3/12	6/12
	<b>&gt; 4</b>	17	3/20	1/20	5/20	11/20	3/20	6/20	4/20	7/20
<b>Breslow grouped</b>	<b>≤ 2</b>	30	7/37	2/37	12/37	16/37	7/37	5/37	16/37	9/37
	<b>&gt; 2</b>	28	3/31	4/31	7/31	17/31	3/31	8/31	7/31	13/31